Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Monocyte activation in multiple sclerosis

A T Reder1, K Genç, P V Byskosh

  • 1Department of Neurology, University of Chicago, Illinois 60637, USA.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|October 8, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic variation near IRF8 is associated with serologic and cytokine profiles in systemic lupus erythematosus and multiple sclerosis.

Genes and immunity·2013
Same author

Cryoballoon ablation for atrial fibrillation guided by real-time three-dimensional transoesophageal echocardiography: a feasibility study.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2013
Same author

Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis.

The pharmacogenomics journal·2012
Same author

Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology.

Neurology·2012
Same author

Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.

Neurology·2012
Same author

Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS).

Multiple sclerosis (Houndmills, Basingstoke, England)·2011
Same journal

Impact of multiple sclerosis disease-modifying therapies on chronic lesion tissue expansion.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Tobacco smoking disrupts bile acid and tryptophan metabolism in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Missed radiologic disease activity by conventional side-by-side MRI comparison is associated with future disease activity in multiple sclerosis: Adopting semiautomated coregistration-fusion into clinical practice.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Longitudinal magnetic resonance spectroscopy study of metabolite changes over 2 years in relapsing and primary progressive multiple sclerosis treated with ocrelizumab.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Racial identity, marginalization, and depression in pediatric-onset multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Disability and race in MS: Does socioeconomic disadvantage play a role?

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
See all related articles

Monocytes play a key role in central nervous system (CNS) inflammation in multiple sclerosis (MS). Targeting monocyte functions offers a promising avenue for developing effective immune therapies for MS patients.

Area of Science:

  • Neuroimmunology
  • Immunology
  • Cellular Biology

Background:

  • Monocytes, macrophages, and microglia are central to CNS inflammation in multiple sclerosis (MS).
  • Monocytes are implicated in the early stages of MS pathogenesis.
  • Peripheral blood monocytes release prostaglandins preceding MS attacks.

Purpose of the Study:

  • To investigate the role of monocytes in MS pathogenesis.
  • To explore the potential of manipulating monocyte functions for MS immune therapy.

Main Methods:

  • Analysis of monocyte activation markers during clinical activity.
  • Quantification of cytokine levels (IL-1, TNF-alpha, IL-10) in MS patients.
  • Assessment of IL-10 mRNA expression in mononuclear cells (MNC) during stable disease.

Related Experiment Videos

Main Results:

  • Monocyte activation markers and pro-inflammatory cytokines (IL-1, TNF-alpha) increase during MS clinical activity.
  • Anti-inflammatory cytokine IL-10 and its mRNA are elevated during stable MS, suggesting a regulatory role.
  • Peripheral blood monocytes secrete prostaglandins before MS attacks.

Conclusions:

  • Monocyte activity and their secreted products significantly influence CNS inflammation in MS.
  • Modulating monokine secretion and monocyte surface protein expression presents a viable strategy for MS immunotherapy.